At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
AZD4017 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure
In Brief
A Phase 2 clinical trial evaluating AZD4017 and Placebo for Raised Intraocular Pressure. Completed, enrolled 50 participants across 11 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRaised Intraocular Pressure
CountriesSweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartDec 2010
Primary CompletionNov 2012
TodayJul 2026
First PostedAug 2, 2010
Enrollment StartDec 1, 2010
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 15.9 years ago
Interventions
AZD4017drug
tablet, oral, one tablet once daily, 28 days
Placebodrug
matching placebo tablet, oral, one tablet once daily, 28 days
AZD4017drug
tablet, oral 2 tablets twice daily, 28 days
Placebodrug
matching placebo tablets, oral, 2 tablets twice daily, 28 days